248 related articles for article (PubMed ID: 26143754)
1. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
Ou Y; Zhai D; Wu N; Li X
Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
[TBL] [Abstract][Full Text] [Related]
2. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
3. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
Yin W; Nie Y; Zhang Z; Xie L; He X
Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1.
He H; Tian W; Chen H; Deng Y
Mol Med Rep; 2016 Feb; 13(2):1923-9. PubMed ID: 26718267
[TBL] [Abstract][Full Text] [Related]
5. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer.
Zhang R; Li Y; Dong X; Peng L; Nie X
Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050
[TBL] [Abstract][Full Text] [Related]
6. Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells.
Jiang C; Long J; Liu B; Xie X; Kuang M
Biomed Res Int; 2015; 2015():572738. PubMed ID: 26078955
[TBL] [Abstract][Full Text] [Related]
7. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.
Xu N; Zhang J; Shen C; Luo Y; Xia L; Xue F; Xia Q
Biochem Biophys Res Commun; 2012 Jul; 423(4):826-31. PubMed ID: 22713463
[TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
11. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
13. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M
Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.
Zhang Y; Tie Q; Bao Z; Shao Z; Zhang L
Comput Math Methods Med; 2021; 2021():6468405. PubMed ID: 34812269
[TBL] [Abstract][Full Text] [Related]
15. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC.
Xu J; Wang Y; Zhang Y; Dang S; He S
Biomed Pharmacother; 2018 Nov; 107():1682-1691. PubMed ID: 30257386
[TBL] [Abstract][Full Text] [Related]
16. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
18. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.
Yang Y; Yang Z; Zhang R; Jia C; Mao R; Mahati S; Zhang Y; Wu G; Sun YN; Jia XY; Aimudula A; Zhang H; Bao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34096570
[TBL] [Abstract][Full Text] [Related]
19. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Azumi J; Tsubota T; Sakabe T; Shiota G
Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
[TBL] [Abstract][Full Text] [Related]
20. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
